MedTrace Logo

Safety and Tolerability Study of IV ST266 in COVID-19 Subjects

NCT04720378 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-06-15

No results posted yet for this study

Summary

The primary aim of the study is to evaluate the safety and tolerability of open-label ST266 given to subjects with confirmed COVID-19 infection through IV administration once a day of 5 consecutive days.

Conditions

Interventions

BIOLOGICAL

ST266

1X ST266

Sponsors & Collaborators

  • IQVIA Biotech

    collaborator INDUSTRY

  • Noveome Biotherapeutics, formerly Stemnion

    lead INDUSTRY

Principal Investigators

  • David L Steed, MD · Noveome Biotherapeutics, Inc

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-30
Primary Completion
2022-05-03
Completion
2022-05-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04720378 on ClinicalTrials.gov